Global health social technologies: reflections on evolving theories and landscapes

This paper has two core purposes. First, building on Nelson and Sampat's work, we outline the social technology conceptual framework and explain why we favour using it to explore two global health initiatives. Second, we discuss the evolution of those initiatives through the lens of the interaction between social technologies, physical technologies and general institutions. Thus we reflect both on evolving conceptual landscapes on the one hand and organisational and institutional terrains on the other. The first section of the paper presents an intellectual journey and outlines our understanding and adoption of the social technology conceptual framework. This framework we argue has a number of advantages over alternative theoretical approaches and perspectives. The second section describes the context in which product development partnerships (PDPs), a type of global health initiative based on a public-private partnership (PPP), have arisen. The third section develops case studies of the International AIDS Vaccine Initiative (IAVI) and the Malaria Vaccines Initiative (MVI) as social technology experiments and looks at the complex dynamics between organisation, management, scientific and RD classifications which we argue are useful in analysing the different roles taken on by these PDPs. In the conclusion we reflect on the useful ways in which the concept of social technologies can shed light on complex and networked initiatives.

[1]  Paul DiMaggio Culture and cognition , 1997 .

[2]  J. Guzman,et al.  The New Landscape of Neglected Disease Drug Development , 2005 .

[3]  Susan Leigh Star,et al.  Institutional Ecology, `Translations' and Boundary Objects: Amateurs and Professionals in Berkeley's Museum of Vertebrate Zoology, 1907-39 , 1989 .

[4]  G. Myrdal Economic theory and underdeveloped regions , 1965 .

[5]  R. Hanlin International product development partnerships: Innovation for better health? , 2009 .

[6]  C. Elias Essay: Can we ensure health is within reach for everyone? , 2006, The Lancet.

[7]  A. Towse,et al.  Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty , 2002 .

[8]  David C. Mowery,et al.  Sources of Industrial Leadership , 1999 .

[9]  D. Rodrik Industrial Policy for the Twenty-First Century , 2004 .

[10]  Karen A. Cerulo Culture in Mind : Toward a Sociology of Culture and Cognition , 2001 .

[11]  Joanna Chataway,et al.  The International AIDS Vaccine Initiative (IAVI): Is it Getting New Science and Technology to the World's Neglected Majority? , 2006 .

[12]  Louis Galambos,et al.  Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation , 1998, Business History Review.

[13]  R. Nelson,et al.  Making Sense of Institutions as a Factor Shaping Economic Performance (Spanish Version) , 2001 .

[14]  Norman Clark,et al.  The political economy of science and technology , 1985 .

[15]  Scott Stern,et al.  The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research , 1999 .

[16]  S. Schwartzman,et al.  The New Production of Knowledge: The Dynamics of Science and Research in Contemporary Societies , 1994 .

[17]  J. Chataway,et al.  Building the Case for Systems of Health Innovation in Africa , 2009 .

[18]  Susan Leigh Star,et al.  Sorting Things Out: Classification and Its Consequences , 1999 .

[19]  Martin Bell,et al.  UNCTAD The Least Developed Countries Report 2007 Background Paper Technological Learning and the Development of Production and Innovative Capacities in the Industry and Infrastructure Sectors of the Least Developed Countries: What Roles for ODA? , 2007 .

[20]  Richard Smith Vaccines and medicines for the world's poorest , 2000, BMJ : British Medical Journal.

[21]  R. Nelson What enables rapid economic progress: What are the needed institutions , 2008 .

[22]  M. Demoitié,et al.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.

[23]  R. Ramlogan,et al.  Innovation systems and the competitive process in developing economies , 2008 .

[24]  K. Pavitt,et al.  Knowledge Specialization, Organizational Coupling, and the Boundaries of the Firm: Why Do Firms Know More than They Make? , 2001 .

[25]  J. Chataway,et al.  Participation, Communication and Innovation: Thinking About the International AIDS Vaccine Initiative , 2005 .

[26]  Jennifer M. Brinkerhoff,et al.  Partnerships Between International Donors and Non-Governmental Development Organizations: Opportunities and Constraints , 2004 .

[27]  K. Knorr-Cetina,et al.  Advances in social theory and methodology : toward an integration of micro- and macro-sociologies , 1981 .

[28]  Albert O. Hirschman,et al.  The strategy of economic development , 1959 .

[29]  I. Cockburn,et al.  Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery , 2003 .

[30]  David Wield,et al.  OECD International Futures Project on “The Bioeconomy to 2030: Designing a Policy Agenda”. Health Biotechnology to 2030 , 2007 .

[31]  David Wield,et al.  Health Biotechnology to 2030 , 2007 .

[32]  David Wield,et al.  Technological Trends and Opportunities to Combat Diseases of the Poor in Africa: A Background Policy Paper prepared for NEPAD in advance of the AMCOST meeting and the African Union Summit , 2009 .

[33]  G. Enterprise,et al.  The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan , 2005, PLoS medicine.

[34]  B. Latour Reassembling the Social: An Introduction to Actor-Network-Theory , 2005 .

[35]  R. Nelson,et al.  Public research institutions and economic catch-up , 2007 .

[36]  Andrew B. Hargadon,et al.  Technology brokering and innovation in a product development firm. , 1997 .

[37]  J. Chataway,et al.  Knowledge Ecologies and Ecosystems? An Empirically Grounded Reflection on Recent Developments in Innovation Systems Theory , 2009 .

[38]  David Wield,et al.  From Followers to Leaders: Managing Technology and Innovation , 2002 .

[39]  Rebecca Henderson,et al.  Sources of Industrial Leadership: The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change , 1999 .

[40]  D. Foley Adam's Fallacy: A Guide to Economic Theology , 2006 .

[41]  Stefano Brusoni,et al.  The International AIDS Vaccine Initiative (IAVI) in a Changing Landscape of Vaccine Development: A Public/Private Partnership as Knowledge Broker and Integrator , 2007, Promoting Innovation, Productivity and Industrial Growth and Reducing Poverty.

[42]  G. Walt,et al.  Global public-private partnerships: Part I--A new development in health? , 2000, Bulletin of the World Health Organization.